NZ504353A - Porous greasy or non-greasy hydroxyapatite ceramic particles and a greasy, oily or sticky excipient as carriers for drug substances - Google Patents
Porous greasy or non-greasy hydroxyapatite ceramic particles and a greasy, oily or sticky excipient as carriers for drug substancesInfo
- Publication number
- NZ504353A NZ504353A NZ504353A NZ50435398A NZ504353A NZ 504353 A NZ504353 A NZ 504353A NZ 504353 A NZ504353 A NZ 504353A NZ 50435398 A NZ50435398 A NZ 50435398A NZ 504353 A NZ504353 A NZ 504353A
- Authority
- NZ
- New Zealand
- Prior art keywords
- greasy
- oily
- pharmaceutically active
- active substance
- sticky
- Prior art date
Links
- 239000000919 ceramic Substances 0.000 title claims abstract description 13
- 239000002245 particle Substances 0.000 title claims description 30
- 229910052588 hydroxylapatite Inorganic materials 0.000 title claims description 20
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 title claims description 17
- 229940088679 drug related substance Drugs 0.000 title description 3
- 239000000969 carrier Substances 0.000 title description 2
- 239000000546 pharmaceutical excipient Substances 0.000 title 1
- 239000000126 substance Substances 0.000 claims abstract description 26
- 239000013543 active substance Substances 0.000 claims abstract description 19
- 238000012377 drug delivery Methods 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000010954 inorganic particle Substances 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 6
- ZMHOBBKJBYLXFR-BPNWFJGMSA-N 4-[(2r)-3-[ethyl(3-propylsulfinylpropyl)amino]-2-hydroxypropoxy]benzonitrile Chemical compound CCCS(=O)CCCN(CC)C[C@@H](O)COC1=CC=C(C#N)C=C1 ZMHOBBKJBYLXFR-BPNWFJGMSA-N 0.000 claims description 12
- 229950003699 almokalant Drugs 0.000 claims description 12
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 9
- 229960003580 felodipine Drugs 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 235000011468 Albizia julibrissin Nutrition 0.000 claims description 8
- 241001070944 Mimosa Species 0.000 claims description 8
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical group C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 7
- 229960002137 melagatran Drugs 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 238000000870 ultraviolet spectroscopy Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000001828 Gelatine Substances 0.000 claims 1
- 108090000190 Thrombin Proteins 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229960004072 thrombin Drugs 0.000 claims 1
- 238000004090 dissolution Methods 0.000 description 10
- 239000012738 dissolution medium Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- BNZPFJBUHRBLNB-UHFFFAOYSA-N 1-oxido-1,2,4-benzotriazin-1-ium Chemical compound C1=CC=C2[N+]([O-])=NC=NC2=C1 BNZPFJBUHRBLNB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical compound NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229950003291 inogatran Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9704400A SE9704400D0 (sv) | 1997-11-28 | 1997-11-28 | Porous inorganic particles as carriers for drug substances |
| PCT/SE1998/002089 WO1999027912A1 (en) | 1997-11-28 | 1998-11-19 | Porous hydroxyapatite particles as carriers for drug substances |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ504353A true NZ504353A (en) | 2001-10-26 |
Family
ID=20409177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ504353A NZ504353A (en) | 1997-11-28 | 1998-11-19 | Porous greasy or non-greasy hydroxyapatite ceramic particles and a greasy, oily or sticky excipient as carriers for drug substances |
Country Status (26)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9924334D0 (en) * | 1999-10-15 | 1999-12-15 | Secr Defence | Pharmaceutical products and methods of fabrication therefor |
| BR0109991A (pt) * | 2000-04-11 | 2003-05-27 | Sankyo Co | Composição farmacêutica |
| IT1319202B1 (it) | 2000-10-12 | 2003-09-26 | Nicox Sa | Farmaci per le malattie a base infiammatoria. |
| US6462021B1 (en) | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
| CN100513398C (zh) | 2002-12-03 | 2009-07-15 | Axys药物公司 | 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物 |
| KR101207553B1 (ko) | 2005-06-02 | 2012-12-03 | (주)씨앤팜 | 금속 이중층 수산화물을 포함하는 생체 주사제용 약물 담체 |
| TW200806648A (en) * | 2005-11-29 | 2008-02-01 | Sankyo Co | Acid addition salts of dihydropyridine derivatives |
| TW200736245A (en) * | 2005-11-29 | 2007-10-01 | Sankyo Co | Acid addition salts of optically active dihydropyridine derivatives |
| JP5027410B2 (ja) * | 2005-12-13 | 2012-09-19 | 株式会社サンギ | ユビキノン含有組成物 |
| US20100040668A1 (en) * | 2006-01-12 | 2010-02-18 | Rutgers, The State University Of New Jersey | Biomimetic Hydroxyapatite Composite Materials and Methods for the Preparation Thereof |
| US8287914B2 (en) * | 2006-01-12 | 2012-10-16 | Rutgers, The State University Of New Jersey | Biomimetic hydroxyapatite synthesis |
| AU2007224651B8 (en) * | 2006-03-14 | 2011-10-27 | Lidds Ab | Bioresorbable controlled-release composition |
| GB0909460D0 (en) | 2009-06-02 | 2009-07-15 | Intrinsiq Materials Global Ltd | Mesoporus material |
| WO2014120922A1 (en) | 2013-02-01 | 2014-08-07 | W. R. Grace & Co.-Conn. | Porous silica gel as a carrier for liquid technologies |
| WO2015040212A1 (en) * | 2013-09-20 | 2015-03-26 | Tillotts Pharma Ag | Delayed release pharmaceutical formulation |
| CN104133014B (zh) * | 2014-07-16 | 2015-09-16 | 广州法尔麦兰药物技术有限公司 | 一种考察布洛伪麻缓释制剂释放度的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8413191D0 (en) | 1984-05-23 | 1984-06-27 | Beecham Group Plc | Pharmaceutical composition |
| GB8713263D0 (en) | 1987-06-05 | 1987-07-08 | Unilever Plc | Spheroidal silica |
| EP0376331A3 (en) | 1988-12-29 | 1991-03-13 | Asahi Kogaku Kogyo Kabushiki Kaisha | Slow release drug delivery granules and process for production thereof |
| US5149523A (en) * | 1989-06-20 | 1992-09-22 | Aktiebolaget Hassle | Polystyrenesulfonate-drug complex and solid dosage forms thereof |
| DE4028906A1 (de) * | 1990-09-12 | 1992-03-19 | Paz Arzneimittelentwicklung | Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen |
| US5443459A (en) * | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
| US5834496A (en) * | 1991-12-02 | 1998-11-10 | Sepracor, Inc. | Methods for treating hypertension using optically pure S(-) felodipine |
| US5947893A (en) * | 1994-04-27 | 1999-09-07 | Board Of Regents, The University Of Texas System | Method of making a porous prothesis with biodegradable coatings |
| US6096324A (en) * | 1995-06-13 | 2000-08-01 | Laboratory Skin Care | Methods of delivering materials into the skin, and compositions used therein |
| JP3562878B2 (ja) * | 1995-07-07 | 2004-09-08 | 丸尾カルシウム株式会社 | 花弁状多孔質ヒドロキシアパタイト微粒子及びその製造方法 |
-
1997
- 1997-11-28 SE SE9704400A patent/SE9704400D0/xx unknown
-
1998
- 1998-10-27 TW TW087117781A patent/TW524694B/zh not_active IP Right Cessation
- 1998-11-16 ZA ZA9810463A patent/ZA9810463B/xx unknown
- 1998-11-16 AR ARP980105798A patent/AR016683A1/es not_active Application Discontinuation
- 1998-11-18 US US09/214,318 patent/US6558703B1/en not_active Expired - Fee Related
- 1998-11-19 SK SK660-2000A patent/SK6602000A3/sk unknown
- 1998-11-19 ES ES98957268T patent/ES2210840T3/es not_active Expired - Lifetime
- 1998-11-19 JP JP2000522898A patent/JP2001524513A/ja active Pending
- 1998-11-19 DK DK98957268T patent/DK1032370T3/da active
- 1998-11-19 PL PL98340927A patent/PL340927A1/xx unknown
- 1998-11-19 CN CN98811634A patent/CN1280492A/zh active Pending
- 1998-11-19 CA CA002311780A patent/CA2311780A1/en not_active Abandoned
- 1998-11-19 PT PT98957268T patent/PT1032370E/pt unknown
- 1998-11-19 WO PCT/SE1998/002089 patent/WO1999027912A1/en not_active Ceased
- 1998-11-19 DE DE69820674T patent/DE69820674T2/de not_active Expired - Lifetime
- 1998-11-19 EP EP98957268A patent/EP1032370B1/en not_active Expired - Lifetime
- 1998-11-19 AU AU13563/99A patent/AU752044B2/en not_active Ceased
- 1998-11-19 BR BR9814751-0A patent/BR9814751A/pt not_active IP Right Cessation
- 1998-11-19 AT AT98957268T patent/ATE256453T1/de not_active IP Right Cessation
- 1998-11-19 IL IL13614698A patent/IL136146A0/xx unknown
- 1998-11-19 RU RU2000113731/15A patent/RU2219907C2/ru not_active IP Right Cessation
- 1998-11-19 KR KR1020007005802A patent/KR20010032557A/ko not_active Withdrawn
- 1998-11-19 NZ NZ504353A patent/NZ504353A/en unknown
- 1998-11-19 ID IDW20000937A patent/ID24700A/id unknown
- 1998-11-19 HU HU0100303A patent/HUP0100303A3/hu unknown
-
2000
- 2000-05-26 NO NO20002719A patent/NO20002719L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU1356399A (en) | 1999-06-16 |
| ES2210840T3 (es) | 2004-07-01 |
| JP2001524513A (ja) | 2001-12-04 |
| EP1032370B1 (en) | 2003-12-17 |
| DE69820674D1 (de) | 2004-01-29 |
| DE69820674T2 (de) | 2004-09-30 |
| CA2311780A1 (en) | 1999-06-10 |
| US6558703B1 (en) | 2003-05-06 |
| ATE256453T1 (de) | 2004-01-15 |
| EP1032370A1 (en) | 2000-09-06 |
| DK1032370T3 (da) | 2004-03-15 |
| BR9814751A (pt) | 2000-10-03 |
| RU2219907C2 (ru) | 2003-12-27 |
| WO1999027912A1 (en) | 1999-06-10 |
| ID24700A (id) | 2000-08-03 |
| AR016683A1 (es) | 2001-07-25 |
| SE9704400D0 (sv) | 1997-11-28 |
| KR20010032557A (ko) | 2001-04-25 |
| AU752044B2 (en) | 2002-09-05 |
| NO20002719D0 (no) | 2000-05-26 |
| HUP0100303A3 (en) | 2004-03-29 |
| IL136146A0 (en) | 2001-05-20 |
| NO20002719L (no) | 2000-07-28 |
| PT1032370E (pt) | 2004-05-31 |
| TW524694B (en) | 2003-03-21 |
| CN1280492A (zh) | 2001-01-17 |
| HUP0100303A2 (hu) | 2001-08-28 |
| ZA9810463B (en) | 1999-05-21 |
| PL340927A1 (en) | 2001-03-12 |
| SK6602000A3 (en) | 2001-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1032370B1 (en) | Porous hydroxyapatite particles as carriers for drug substances | |
| CA1304294C (en) | Pharmaceutical preparations with extended release | |
| KR100415897B1 (ko) | 생체 이용율이 높은 페노피브레이트 제약학적 조성물 | |
| CN101252920B (zh) | 包含替诺福韦、表面活性剂、依法韦仑和恩曲他滨的稳定固定剂量的单位制剂 | |
| US6555138B1 (en) | Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances | |
| US20080248101A1 (en) | Pharmaceutical composition containing fenofibrate and method for the preparation thereof | |
| TWI285116B (en) | Drug delivery system for enhanced bioavailability of hydrophobic active ingredients | |
| CA2127166C (en) | Sustained release morphine compositions and a method of preparation | |
| CA2393588A1 (en) | Solid oral dosage form | |
| KR20040058103A (ko) | 신규 개질 방출 제제 | |
| EP2153834A2 (en) | Extended release pharmaceutical compositions comprising quetiapine salts | |
| Sun et al. | A microcrystalline cellulose based drug-composite formulation strategy for developing low dose drug tablets | |
| KR100380841B1 (ko) | 데소게스트렐(desogestrel)을함유하는정제또는캡슐 | |
| MXPA00005116A (en) | Porous hydroxyapatite particles as carriers for drug substances | |
| CZ20001946A3 (cs) | Porézní částice hydroxyapatitu jako nosiče léčivých substancí | |
| JP2002501022A (ja) | 副作用の少ない持続放出性チアガビン製剤 | |
| CZ20002675A3 (cs) | Tiagabinové prostředky s prodlouženým uvolňováním se sníženými vedlejšími účinky | |
| MXPA00005112A (en) | Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances | |
| CZ20001945A3 (cs) | Pelety z polyethylenglykolové matrice pro mastné, olejové nebo lepivé léčivé substance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |